| abstract |
In the general formula (I) of the compounds according to the invention, R 7, R 8, R 9 and R 10 are independently H, F, Cl, Br, OH, NO 2, CN, O-alkyl, O-alkenyl, O-alkynyl, O-SO 2 -alkyl, alkyl, alkenyl or alkynyl wherein the alkyl, alkenyl and alkynyl groups may be optionally substituted with one or more F, Cl or Br substituents; R1 and R2 are independently H, alkyl which may be OH, O-alkyl, NH2, NH-alkyl, N ( alkyl) may be substituted with 2 substituents O-alkyl, CO-alkyl, COO-alkyl, alkylene-COOH or alkylene-COO-alkyl, R3, R4, R5, R6 independently of one another H, F, Cl, Br, NO2, CN, O-R 11, unsubstituted O-phenyl, S-R 11, COOR 11, N (R 12) (R 13), alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkylalkylene, wherein the alkyl groups are optionally one or more of F, Cl, Br. , O-R11, COOR11or N (R16) (R17) wherein R11, R12, R13, R14, R15, R16, and R17 are organic, with the proviso that at least one of R3, R7, R8, R9 and R10 is other than hydrogen and physiologically acceptable salts thereof. The invention relates to pharmaceutical compositions containing the above compounds and to their preparation. The compounds of the invention may be used in the preparation of compounds of formula II. type diabetes. . |